Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CET

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
02/18 ARIAD PHARMACEUTICALS : Medinol Announces Appointment Of Harvey J. Berger, M.D.,..
02/18 TAKEDA PHARMACEUTICAL : Japans Takeda acquires US cancer drug manufacturer ARIAD..
02/16 ARIAD PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Completi..
02/16 ARIAD PHARMACEUTICALS : Announces Submission of Marketing Authorization Applicat..
02/06 ARIAD PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
02/06 LAWSUIT FOR INVESTORS AGAINST ACQUIS : ARIA) Filed
02/06 ARIAD PHARMACEUTICALS : Announces Submission of Marketing Authorization Applicat..
02/03 ARIAD PHARMACEUTICALS : Enters into Definitive Agreement to Be Acquired by Taked..
02/03 ARIAD PHARMACEUTICALS : Takeda to Acquire ARIAD Pharmaceuticals, Inc.
01/26 TAKEDA PHARMACEUTICAL : Commences Cash Tender Offer for All Outstanding Shares o..
More news
Sector news : Bio Therapeutic Drugs
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/23 SEEKING ALPHA INTERVIEWS : Bret Jensen On Promising Drugs And Acquisition Target..
02/16 Icahn Boosts Herbalife Bet While Advising Trump
02/15 Warren Buffett Reveals New Picks - Apple, Airlines, And Arb
02/10 BIOTECH FORUM DAILY DIGEST : Buyout Rumors On The Rise; Aratana Therapeutics' De..
02/09 BIOTECHNOLOGY : Off To New Highs
Advertisement
Financials ($)
More Financials
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christophe M. Bianchi President
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
Liza Heapes Senior Manager-Corporate Communications
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..0.00%0
AMGEN, INC.19.39%129 711
CELGENE CORPORATION2.14%94 741
GILEAD SCIENCES, INC.-2.33%92 881
REGENERON PHARMACEUTIC..-1.66%39 573
ACTELION LTD22.36%28 883
More Results